trending Market Intelligence /marketintelligence/en/news-insights/trending/JUn4F2mqWjNm-kbHjkKuPg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

HHS division, Cytori execute $13.4M contract option

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


HHS division, Cytori execute $13.4M contract option

The Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, signed a contract option valued at about $13.4 million with Cytori Therapeutics Inc.

The executed option will fund Cytori's clinical trial of Cytori Cell Therapy to develop it as a medical countermeasure for thermal burn injury.

According to the company, the contract option increases the authority's overall commitment to Cytori technology to about $34.6 million.

The original contract retains two as-yet unfunded options valued at up to $68 million. The first option is written to support a clinical trial that could potentially follow the present clinical trial on Cytori Cell Therapy and lead to its U.S. FDA approval as a treatment for thermal burn injury.

The second option addresses additional preclinical work targeting application in thermal burn and radiation injury.